Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,624 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.
Mahlangu J, Powell JS, Ragni MV, Chowdary P, Josephson NC, Pabinger I, Hanabusa H, Gupta N, Kulkarni R, Fogarty P, Perry D, Shapiro A, Pasi KJ, Apte S, Nestorov I, Jiang H, Li S, Neelakantan S, Cristiano LM, Goyal J, Sommer JM, Dumont JA, Dodd N, Nugent K, Vigliani G, Luk A, Brennan A, Pierce GF; A-LONG Investigators. Mahlangu J, et al. Among authors: kulkarni r. Blood. 2014 Jan 16;123(3):317-25. doi: 10.1182/blood-2013-10-529974. Epub 2013 Nov 13. Blood. 2014. PMID: 24227821 Free PMC article. Clinical Trial.
Unresolved issues in prophylaxis.
Brown SA, Aledort LM, Astermark J, Berntorp E, van den Berg M, Blanchette V, Donfield S, Gringeri A, Hilgartner M, Kulkarni R, Leissinger C, Negrier C, Nuss R, Petterson H, Petrini P, Poulios N, Schramm W; Round Table Group. Brown SA, et al. Among authors: kulkarni r. Haemophilia. 2002 Nov;8(6):817-21. doi: 10.1046/j.1365-2516.2002.00685.x. Haemophilia. 2002. PMID: 12410654 No abstract available.
Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A.
Collins PW, Blanchette VS, Fischer K, Björkman S, Oh M, Fritsch S, Schroth P, Spotts G, Astermark J, Ewenstein B; rAHF-PFM Study Group. Collins PW, et al. J Thromb Haemost. 2009 Mar;7(3):413-20. doi: 10.1111/j.1538-7836.2008.03270.x. Epub 2008 Dec 20. J Thromb Haemost. 2009. PMID: 19143924 Free article. Clinical Trial.
Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring.
Björkman S, Blanchette VS, Fischer K, Oh M, Spotts G, Schroth P, Fritsch S, Patrone L, Ewenstein BM; Advate Clinical Program Group; Collins PW. Björkman S, et al. J Thromb Haemost. 2010 Apr;8(4):730-6. doi: 10.1111/j.1538-7836.2010.03757.x. J Thromb Haemost. 2010. PMID: 20398185 Free PMC article.
The international factor IX treatment network survey.
Berntorp E, Shapiro AD, Waters J, Astermark J; International Factor IX Treatment Network. Berntorp E, et al. Haemophilia. 2012 May;18(3):e60-2. doi: 10.1111/j.1365-2516.2012.02767.x. Epub 2012 Mar 8. Haemophilia. 2012. PMID: 22404549 No abstract available.
Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics.
Kulkarni R, Karim FA, Glamocanin S, Janic D, Vdovin V, Ozelo M, Rageliene L, Carboni E, Laguna P, Dobaczewski G, Seremetis S, Lindblom A, Santagostino E. Kulkarni R, et al. Haemophilia. 2013 Sep;19(5):698-705. doi: 10.1111/hae.12165. Epub 2013 May 8. Haemophilia. 2013. PMID: 23651313 Clinical Trial.
Global Emerging HEmophilia Panel (GEHEP): A Multinational Collaboration for Advancing Hemophilia Research and Treatment.
James P, Kasthuri R, Kruse-Jarres R, Soni A, Kulkarni R, Bidlingmaier C, Chitlur M, Fogarty P, Gomez K, Holm PA, Mahlangu J, Mancuso ME, Mingot-Castellano ME, Dolan G. James P, et al. Among authors: kulkarni r. Transfus Med Hemother. 2013 Oct;40(5):352-5. doi: 10.1159/000354843. Epub 2013 Aug 26. Transfus Med Hemother. 2013. PMID: 24273489 Free PMC article. Review.
Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels.
Shapiro AD, Ragni MV, Kulkarni R, Oldenberg J, Srivastava A, Quon DV, Pasi KJ, Hanabusa H, Pabinger I, Mahlangu J, Fogarty P, Lillicrap D, Kulke S, Potts J, Neelakantan S, Nestorov I, Li S, Dumont JA, Jiang H, Brennan A, Pierce GF. Shapiro AD, et al. Among authors: kulkarni r. J Thromb Haemost. 2014 Nov;12(11):1788-800. doi: 10.1111/jth.12723. Epub 2014 Oct 10. J Thromb Haemost. 2014. PMID: 25196897 Free article. Clinical Trial.
1,624 results